Asenapine

• Schizophrenia
• Bipolar Disorder
• Acute Mania
• Psychosis

Asenapine is a second-generation (atypical) antipsychotic prescribed for schizophrenia and acute manic or mixed episodes of bipolar disorder. It stands apart from most oral antipsychotics because the sublingual tablet dissolves under the tongue rather than being swallowed, and the Secuado transdermal patch delivers the same molecule across intact skin. Both routes bypass the substantial first-pass hepatic metabolism that would otherwise destroy the drug if swallowed. For patients who struggle with adherence or have inconsistent gastrointestinal absorption, these alternative delivery routes can make a meaningful clinical difference. Asenapine is one option among many in the psychiatric toolkit, and selection depends on symptom profile, side-effect tolerance, and individual response.

Mechanism of Action

Asenapine is a tetracyclic dibenzo-oxepino pyrrole with a notably broad receptor binding profile. Its therapeutic effects in psychosis and mania arise primarily from antagonism at dopamine D2 receptors in the mesolimbic pathway, which dampens the dopaminergic overactivity associated with positive symptoms such as hallucinations, delusions, and disorganized thinking. Equally important is its potent antagonism at serotonin 5-HT2A receptors, which is thought to enhance dopaminergic tone in the prefrontal cortex and nigrostriatal pathway, potentially improving negative and cognitive symptoms while reducing the risk of extrapyramidal side effects compared with first-generation agents.

Beyond these core targets, asenapine binds with high affinity to 5-HT2C, 5-HT6, 5-HT7, dopamine D1, D3, and D4, alpha-1 and alpha-2 adrenergic receptors, and histamine H1 receptors. The 5-HT2C and H1 affinity contributes to weight gain and sedation; alpha-1 blockade explains the orthostatic hypotension seen on initiation. Notably, asenapine has minimal anticholinergic activity, so dry mouth, constipation, and cognitive blunting are less prominent than with some older antipsychotics. The sublingual route allows the molecule to enter the systemic circulation directly through oral mucosa, achieving roughly 35 percent bioavailability compared with under 2 percent if swallowed. The transdermal patch maintains steady-state plasma concentrations across 24 hours, smoothing out peaks and troughs that can drive transient side effects.

Clinical Use

Asenapine is FDA-approved for the acute treatment of schizophrenia in adults, the acute treatment of manic or mixed episodes of bipolar I disorder as monotherapy or adjunct to lithium or valproate in adults, maintenance therapy for bipolar I in adults, and acute mania in pediatric patients aged 10 to 17. In treatment algorithms it is generally considered after first-line atypicals such as risperidone, aripiprazole, or quetiapine have proven inadequate or poorly tolerated. The American Psychiatric Association schizophrenia guidelines emphasize that antipsychotic selection should be individualized based on prior response, side-effect profile, comorbidities, and patient preference rather than rigid hierarchy.

The sublingual formulation can be useful for patients with swallowing difficulties, those receiving other medications that interfere with gastric absorption, or individuals who tend to cheek or palm tablets. The Secuado patch is particularly valuable for patients with marginal adherence to oral regimens, since visual confirmation that a patch is on the body provides a daily check on dosing. Compared with olanzapine and quetiapine, asenapine tends to cause less weight gain and metabolic disturbance, though weight increase still occurs. Compared with risperidone and paliperidone, it carries a somewhat lower burden of prolactin elevation. Patients should be counseled that all atypicals share class risks of metabolic syndrome, sedation, and movement disorders, and that careful matching of drug to patient yields the best long-term outcomes. The U.S. Food and Drug Administration provides labeling details at accessdata.fda.gov.

How to Take It

The sublingual tablet must be removed from the blister pack with dry hands and placed under the tongue, where it dissolves completely in about 10 seconds. Patients should not chew, crush, or swallow the tablet, and should avoid eating or drinking for at least 10 minutes after a dose to allow full mucosal absorption. The tablets are flavored — most strengths use a black cherry flavor — to improve acceptability. The transdermal patch is applied once daily to clean, dry, intact skin on the upper arm, upper back, abdomen, or hip, rotating sites with each application to minimize skin irritation. The old patch should be removed before applying a new one.

Dosing for schizophrenia typically begins at 5 mg twice daily and can be increased to 10 mg twice daily after a week if tolerated. For bipolar mania monotherapy, treatment often starts at 10 mg twice daily with downward adjustment for tolerability. Missed doses should be taken as soon as remembered unless it is nearly time for the next dose, in which case the missed dose is skipped — doubling up is not appropriate. The first week often brings sedation, mild dizziness on standing, and a peculiar tongue numbness from the sublingual route; these usually fade. Store tablets in the original blister at room temperature.

Monitoring and Follow-Up

Because atypical antipsychotics carry meaningful metabolic risk, baseline and ongoing monitoring is essential. Before starting, clinicians should document weight and waist circumference, fasting glucose or hemoglobin A1c, fasting lipid panel, blood pressure, and a personal and family history of diabetes and cardiovascular disease. An ECG is reasonable in patients with cardiac risk factors given asenapine's modest QT-prolonging potential. Weight should be checked at every visit, with concern triggered by gains exceeding 5 percent of baseline. Fasting glucose and lipids are typically rechecked at 3 months and then annually, with more frequent assessment if metabolic abnormalities emerge — fasting glucose above 126 mg/dL, A1c at or above 6.5 percent, LDL above 130 mg/dL, or triglycerides above 200 mg/dL all warrant intervention.

Abnormal involuntary movements should be assessed at baseline and at least every 6 months using a structured tool such as the AIMS scale, watching for early signs of tardive dyskinesia. Prolactin should be measured if galactorrhea, menstrual irregularity, or sexual dysfunction develops. Patients with risk factors for stroke or cardiovascular disease deserve closer blood pressure surveillance. The MedlinePlus medication entry at medlineplus.gov summarizes patient-facing information.

Special Populations

Elderly patients with dementia-related psychosis must not receive asenapine — a class boxed warning highlights increased mortality, primarily from cardiovascular events and infection. In otherwise healthy elderly adults, lower starting doses and slower titration help limit orthostatic hypotension and sedation. No dose adjustment is needed for mild to moderate hepatic impairment, but severe hepatic impairment (Child-Pugh C) is a contraindication because drug exposure rises substantially. Renal impairment of any degree generally requires no adjustment.

Pregnancy data are limited; antipsychotic exposure in the third trimester has been linked to extrapyramidal and withdrawal symptoms in newborns, and decisions to continue or stop therapy should weigh maternal mental-health stability against these risks. Asenapine is excreted in animal milk; human data are sparse, so breastfeeding requires individualized counseling. Pediatric efficacy is established for bipolar mania between ages 10 and 17, but adolescents experience more weight gain and sedation than adults and need particularly close metabolic monitoring.

When to Contact Your Doctor

Seek emergency care for high fever combined with muscle rigidity, confusion, or autonomic instability — these can signal neuroleptic malignant syndrome. Sudden swelling of the face, tongue, or throat, severe rash, or wheezing after a sublingual dose may indicate a serious oral or systemic hypersensitivity reaction. Fainting or near-fainting on standing, palpitations, chest pain, or new shortness of breath warrant urgent evaluation. Persistent involuntary movements of the face, tongue, or limbs may represent tardive dyskinesia and should prompt review of therapy. New thoughts of self-harm, marked worsening of mood, or increased agitation should be reported immediately. Excessive thirst, frequent urination, or unintentional weight gain may suggest emerging metabolic complications.

Patients should also report any new movement difficulties, persistent muscle stiffness, fine tremor, or slowed movement that may suggest drug-induced parkinsonism, since early recognition allows dose adjustment before symptoms become disabling. Sudden inability to sit still, an inner sense of restlessness, or pacing may represent akathisia and is often distressing enough to warrant medication adjustment or addition of a beta blocker. Signs of infection should be reported because clozapine and some other antipsychotics can rarely affect blood counts. The American Psychiatric Association practice guideline for schizophrenia and the National Alliance on Mental Illness offer additional patient and family resources.

If you have questions about asenapine or want to review whether it is the right antipsychotic for your situation, contact us or schedule a visit with the Zimmer Medical Group team for personalized assessment and ongoing monitoring.